Cantor Fitzgerald Estimates Belite Bio FY2025 Earnings

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Belite Bio in a note issued to investors on Monday, November 24th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will post earnings per share of ($2.26) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $154.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. Cantor Fitzgerald also issued estimates for Belite Bio’s FY2026 earnings at ($3.04) EPS.

BLTE has been the subject of a number of other reports. HC Wainwright reduced their target price on shares of Belite Bio from $100.00 to $98.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Wall Street Zen lowered Belite Bio from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Benchmark increased their price objective on Belite Bio from $80.00 to $132.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Mizuho started coverage on Belite Bio in a research note on Thursday, November 20th. They issued a “neutral” rating and a $105.00 target price on the stock. Finally, Zacks Research raised Belite Bio from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 16th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $122.25.

Belite Bio Stock Up 1.4%

Shares of BLTE stock opened at $129.62 on Wednesday. Belite Bio has a 12-month low of $49.00 and a 12-month high of $144.99. The firm has a fifty day moving average of $95.67 and a 200-day moving average of $74.83. The company has a market capitalization of $4.52 billion, a price-to-earnings ratio of -67.51 and a beta of -1.42.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Monday, November 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12).

Hedge Funds Weigh In On Belite Bio

Several hedge funds and other institutional investors have recently made changes to their positions in BLTE. Alyeska Investment Group L.P. bought a new stake in Belite Bio during the first quarter worth $5,538,000. EverSource Wealth Advisors LLC acquired a new position in shares of Belite Bio during the 2nd quarter worth about $147,000. Marshall Wace LLP bought a new stake in shares of Belite Bio in the 2nd quarter valued at about $547,000. BNP Paribas Financial Markets acquired a new stake in Belite Bio in the 2nd quarter valued at about $190,000. Finally, GAMMA Investing LLC grew its holdings in Belite Bio by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after purchasing an additional 176 shares during the period. 0.53% of the stock is owned by institutional investors.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.